ArticleThoracic cancer2026
Surgical Result for Patients Who Simultaneously Presented With Myasthenia Gravis and Thymoma.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients who present concurrently with thymoma and myasthenia gravis (MG) constitute a unique clinical population in whom both oncologic control and stabilization of MG symptoms are essential treatment goals. Although extended thymectomy is traditionally recommended, the necessity of radical thymic tissue removal in this subgroup remains uncertain. This study compared surgical outcomes between thymomectomy and extended thymectomy in this specific population.
methodsWe retrospectively analyzed 145 patients with concurrent thymoma and MG treated across four tertiary centers between 2013 and 2023. Clinical characteristics, surgical approaches, postoperative complications, MG medication adjustments, and plasmapheresis requirements were compared between patients undergoing thymomectomy (n = 37) and extended thymectomy (n = 108). A 1:1 propensity score matching (PSM) was performed to balance age (n = 37 per group). Freedom from recurrence (FFR) and overall survival (OS) were compared between patients undergoing thymomectomy and extended thymectomy.
resultsPatients undergoing thymomectomy were older with higher anesthesia risk. Despite a higher rate of R1 resections, thymomectomy achieved FFR and OS comparable to extended thymectomy across the entire cohort and within different Masaoka stages. No significant differences were observed in MG medication reduction, plasmapheresis rates, or postoperative MG crisis. Thymomectomy was associated with shorter operative times and avoided the risks related to thymic vein division, a major source of hemorrhagic complications in extended thymectomy.
conclusionThymomectomy provides oncologic and neurologic outcomes comparable to extended thymectomy in patients with thymoma-associated MG while reducing operative risks. These findings challenge the necessity of routine extended thymectomy and support thymomectomy as an effective, less invasive alternative in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.